Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
The purpose of this study is to determine whether Ingavirin® 90 mg once daily is effective and safe for the treatment of influenza and other laboratory confirmed acute respiratory viral infections in the course of standard therapy in patients 18-60 years old.
Epistemonikos ID: e247353e475fe7c1688380e1764ada1c26b48a2f
First added on: Mar 23, 2020